"Clinical Utility of the XF-1600 Flow Cytometer for MRD Assessment in Multiple Myeloma"

Multiple myeloma (MM) is a plasma cell neoplasm with an incidence of 1 – 1.8% of all cancers, and the second most common hematological cancer. Despite the significant improvements in treatment and management, this neoplasm poses a significant challenge to healthcare providers and patients alike, since 85 – 90% of patients eventually relapse.